Medicines Discovery Catapult launches a Virtual R&D Discovery Services platform made up of more than 20 CROs, which will help support small- to medium-sized companies deliver drug discovery projects.
The Danish company is set to use only renewable electricity to run its global production facilities by 2020, after an investment of $70m in a 672-acre solar panel installation.
An international coalition of health integrity groups today demands that European universities must make clinical trial results public – with 83% all of due trials still unreported, according to a new report.
Smaller company’s last year led in new drug approvals, nearly half of which were for the treatment of rare diseases, as the industry shifts away from the need to scale infrastructure, says Tufts director.
The Australian Government commits $100m to support rural, regional, and remote clinical trials – recognizing the importance of a “vibrant clinical trial ecosystem in underpinning a world-class health care system,” says industry expert.
Teva begins recall in the US of 35 lots of losartan tablets and Torrent expands its recall to include an additional 104 lots, after trace amounts of NMBA were discovered in both companies' products.
A US trade report identified that counterfeit drugs are becoming a greater issue through illegitimate online sales, particularly in countries such as China and India.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...
Centralized databases, reduced competition for patients, and higher starting doses are among some of the benefits to conducting research in Poland, which ranks seventh in Europe for clinical trial participation, says Moleculin CEO.
Eight site networks team up to form hyperCore International – “the network of networks” – with locations from Lima, Peru to Calgary, Canada, says CEO, who stresses the company's partnership model as key to its success.
GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.
Casey Orvin, named the new president of SCRS earlier this year, aims to ensure that sites “stay in the forefront of the minds of sponsors and CROs” – and have a seat at the table as equal partners in the industry.
The International Vaccine Institute plans to conduct a Phase III clinical trial for a typhoid conjugate vaccine as part of which it will put in place infrastructure and a robust training program, including good clinical practice training.
Using RWD and RWE to make data actionable and patient centric can be a gamechanger in the health care industry’s research capabilities, according to LMC Manna research executive.
Medable has received $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials, which can be used at an individual, study, or population level.
LabCorp’s Covance Drug Development segment is set to acquire Envigo’s nonclinical research services business for $485m – while Envigo will purchase Covance’s research products business.
CPhI North America donates $10,000 to iBIO’s Educate Center to help fund STEM programs for girls and solidifies its partnership with the association to support Illinois as a growing life sciences hub.
On the path to first-in-human clinical trials one of the main challenges is “velocity, ensuring rapid delivery of delivered drug product into the clinical program,” says CDMO.
Oncology and immunotherapies are the top two indications for global clinical research – and are driving a significant growth in the market demand for HPAPIs, says Patheon executive.
Senator Flake will discuss regulatory guidance impacting innovation and his perspective on the state of the industry during his keynote address at CPhI North America.
Jordan-based MS Pharma announces the acquisition of the Greek generic manufacturer Genepharm, aiming to add cardiovascular, CNS and oncology products to its portfolio.
Novotech signs on two major hospitals to its CRO partnership program in South Korea – a market seeing greater interest from North American and European companies.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
Circuit Clinical is providing digital and clinical services as part of its collaboration with a NY-based cancer center, patients at which will have expanded opportunities to participate in clinical trials.
Completion of early-stage development site expansion at the Illinois Science and Technology Park supplies Chicago-based drug companies with refrigeration services for complex APIs.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
Patients in Southern and Eastern Europe wait on average five times as long for the same treatments as patients in Northern and Western Europe, an EFPIA report finds.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Virtual trials are poised to scale, says the CEO of Transparency Life Sciences, which recently conducted a siteless study to assess the feasibility and ease of collecting research-grade clinical data from subjects remotely.
The online marketplace for outsourced research launches its first original service, which will provide researchers with on-demand insights into clinical trials – including trends in what is ‘hot’ and what is ‘not,’ says CBO.
Sharp’s clinical services center is approved by the MHRA and now ready to offer services for serialization and trial management while reducing carbon footprint with the addition of solar panel systems.
Natural history studies provide researchers with a better understanding of a disease’s progression, supporting clinical trial design, among other benefits, say industry experts commenting on the FDA’s new draft guidance.